All In Biotech

Drug Trial Radar · NCT01906658

A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis

Last checked: Nov 20, 2026Latest source record: Jan 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

43

Actual

Start

Jul 2013

Primary completion

Nov 2014

Study completion Dec 2014

Sponsor

Lead sponsor
MallinckrodtIndustry
Sponsor type
Industry
First posted
Jul 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 8-week randomized, open-label evaluation will examine the acute safety and tolerability of 4 different dosing regimens of Acthar to inform dose selection for future studies of Acthar in patients with Amyotrophic Lateral Sclerosis (ALS). The study will also investigate the mean rate of change in the ALSFRS-R total score as an exploratory endpoint to help design future studies. This study will enroll up to 40 patients and include an optional 28-week open-label extension period plus a 3-week treatment taper and 1-week follow up period. After completion of Week 8, patients enrolled in a treatment group that is considered safe and tolerable at that time have the option to continue into the open-label extension period. A 3-week treatment taper and a follow-up visit are planned for all patients enrolled in the study, beginning either at Week 8 or at Week 36 if a patient continues into the optional open-label extension period.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • Repository corticotropin injectionDrug

    Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects With Adverse Events (AEs) That Required Study Drug Discontinuation or Could Not be Controlled With Concomitant MedicationTime frame: Baseline to Week 8

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Questcor Investigational Site

    Birmingham, Alabama

  • Questcor Investigational Site

    Phoenix, Arizona

  • Questcor Investigational Site

    San Francisco, California

  • Questcor Investigational Site

    Stanford, California

  • Questcor Investigational Site

    Jacksonville, Florida

  • Questcor Investigational Site

    Miami, Florida

  • Questcor Investigational Site

    Tampa, Florida

  • Questcor Investigational Site

    Atlanta, Georgia

  • Questcor Investigational Site

    Kansas City, Kansas

  • Questcor Investigational Site

    Rochester, Minnesota

  • Questcor Investigational Site

    Lincoln, Nebraska

  • Questcor Investigational Site

    Hershey, Pennsylvania

  • Questcor Investigational Site

    Pittsburgh, Pennsylvania

  • Questcor Investigational Site

    Memphis, Tennessee

  • Questcor Investigational Site

    Dallas, Texas

  • Questcor Investigational Site

    Houston, Texas

  • Questcor Investigational Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.